[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
News From the Centers for Disease Control and Prevention
December 18, 2002

Discontinuation of Cefixime Tablets—United States

JAMA. 2002;288(23):2963. doi:10.1001/jama.288.23.2963-JWR1218-3-1

MMWR. 2002;51:1052

In July 2002, Wyeth Pharmaceuticals (Collegeville, Pennsylvania) discontinued manufacturing cefixime (Suprax®) in the United States. In October 2002, the company ceased marketing cefixime tablets (200 mg and 400 mg) because of depletion of company inventory. Wyeth's patent for cefixime expired on November 10, 2002. No other pharmaceutical company manufactures or sells cefixime tablets in the United States. Wyeth will continue to sell cefixime suspension (100 mg/5 ml) until March 31, 2003, or until company inventory is depleted, whichever is sooner.

Cefixime is the only CDC-recommended oral antimicrobial agent to which Neisseria gonorrhoeae has not developed significant resistance.1 Uncomplicated N. gonorrhoeae infections may be treated with single-dose regimens of cefixime 400 mg orally, ceftriaxone 125 mg intramuscularly, or an oral fluoroquinolone (ciprofloxacin 500 mg, levofloxacin 250 mg, or ofloxacin 400 mg). However, fluoroquinolones should not be used for treatment of gonorrhea if the infection was acquired in Asia, the Pacific Islands (including Hawaii), or California because the prevalence of fluoroquinolone-resistant N. gonorrhoeae is high in those areas.1,2

×